% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • comstockcir comstockcir Mar 1, 2013 9:53 AM Flag

    ot- INFI hit a 52 week high this morning.. baby PCYC

    own both

    PCYC to a 100.

    INFI to 60 soon

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • abrake Mar 1, 2013 10:09 AM Flag

      This is why.UPDATE: Piper Jaffray Assumes Coverage on Infinity ...March 01, 2013 9:04 AM In a report published Friday, Piper Jaffray assumed coverage on Infinity Pharmaceuticals (NASDAQ: INFI [FREE Stock Trend Analysis]), upgrading its rating from Neutral to Overweight, and raised its price target from $14.00 to $53.00.

      Piper Jaffray noted, “We believe IPI-145 could compete in the multi-billion dollar markets being developed by Pharmacyclics' ibrutinib and Gilead's GS-1101 for hematological malignancies. We are projecting peak sales of $2bn+ in chronic lymphocytic leukemia (CLL), $150mn in mantle cell lymphoma (MCL), and $750mn in follicular lymphoma (FL). Similar to our PCYC thesis, we believe physicians are eager to move away from traditional chemotherapy drugs, and would embrace targeted therapies with relatively benign safety profiles, opening blockbuster opportunities for IPI-145. We expect updated Phase I/II data in hematological malignancies at ASCO (May 31-June 4) and ASH (Dec 7-10) to drive shares in 2013, with positive data in other disorders (i.e., MM, DLBCL, HL,allergic asthma, and RA) to provide further upside.”

      Infinity Pharmaceuticals closed on Thursday at $41.33.

257.100.00(0.00%)Apr 23 3:59 PMEDT